← Back to Search

TNFerade for Prostate Cancer

Phase 1
Waitlist Available
Research Sponsored by GenVec
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histological documented high-risk localized prostate cancer defined by clinical stage >=T3 or Gleason score ≥8
Normal organ function defined by: Hgb > 10 mg/dl (may be transfused or on erythropoietin), Platelets > 100,000/l, Absolute neutrophil count > 1500/l, Bilirubin < 1.5 mg/dl, AST and ALT < 1.5X upper limit of normal
Must not have
Clinical evidence of active infection of any type
History of thrombosis (pulmonary embolism (PE) or deep vein thrombosis (DVT)) or known thrombophilia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test different doses of TNFerade in combination with radiation to see which is the most effective at treating prostate cancer while also having the least side effects.

Who is the study for?
Men with high-risk localized prostate cancer, without distant metastases but possibly with pelvic lymph node involvement. They must have a hemoglobin level above 10 mg/dl, platelets over 100,000/l, and normal liver function. Participants should not have had chemotherapy recently or be unable to undergo daily radiation therapy due to other health issues.
What is being tested?
The trial is testing TNFerade™ Biologic combined with radiation against prostate cancer. TNFerade is an experimental gene transfer therapy designed to enhance the effectiveness of radiation treatment by being injected directly into the tumor.
What are the potential side effects?
Potential side effects are not explicitly listed in the provided information. However, as a gene transfer therapy used alongside radiation, possible side effects could include local reactions at injection sites, fatigue from radiation, and typical risks associated with gene therapies such as immune responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer is aggressive, with a high Gleason score or advanced stage.
Select...
My blood counts and liver function tests are within normal ranges.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I currently have an active infection.
Select...
I have had blood clots or am known to have clotting disorders.
Select...
I am HIV-positive and on combination anti-retroviral therapy.
Select...
I have been on oral steroids higher than 10 mg/day for over 6 months.
Select...
I cannot have prostate radiotherapy due to past pelvic radiation or other health issues.
Select...
I have not had a stroke, heart attack, or any vascular procedure for blocked arteries in the last 6 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: SingleExperimental Treatment1 Intervention
TNFerade™ Biologic + Radiation

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,810 Previous Clinical Trials
8,159,612 Total Patients Enrolled
27 Trials studying Prostate Cancer
6,195 Patients Enrolled for Prostate Cancer
GenVecLead Sponsor
8 Previous Clinical Trials
129 Total Patients Enrolled

Media Library

TNFerade™ Biologic Clinical Trial Eligibility Overview. Trial Name: NCT01048151 — Phase 1
Prostate Cancer Clinical Trial 2023: TNFerade™ Biologic Highlights & Side Effects. Trial Name: NCT01048151 — Phase 1
Prostate Cancer Research Study Groups: Single
TNFerade™ Biologic 2023 Treatment Timeline for Medical Study. Trial Name: NCT01048151 — Phase 1
~13 spots leftby Nov 2025